Court of Appeal upholds PI against Sinocare and Menarini

Abbott’s Patent Fortress Holds: UPC Ruling Reshapes MedTech Risk

The UPC Court of Appeal has dismissed Sinocare and Menarini’s appeal, fully upholding a preliminary injunction granted to Abbott regarding EP 633. This ruling solidifies The Hague’s status as a critical venue for medical device IP enforcement, effectively blocking Chinese competitor Sinocare’s GlucoMen iCan systems from the European market. For investors, this validates Abbott’s defensive moat around its high-margin Continuous Glucose Monitoring (CGM) revenue streams.

Market share in the medical device sector is not won on features alone; it is secured in the courtroom. When a dominant player like Abbott Laboratories faces a low-cost entrant from a jurisdiction with different IP norms, the fiscal threat is immediate. The loss of exclusivity in the European Union—a region contributing significantly to Abbott’s international sales—would compress EBITDA margins on the FreeStyle Libre line, which historically operates at gross margins exceeding 60%. The Court of Appeal’s decision yesterday acts as a firewall, preserving the pricing power Abbott enjoys in the UPC territory.

This is not merely a legal victory; it is a capital preservation event. By maintaining the injunction, Abbott prevents the dilution of its recurring revenue model. In the CGM space, once a patient is onboarded to a specific sensor ecosystem, switching costs are high. Allowing a competitor to flood the market with a potentially infringing, lower-cost alternative disrupts this sticky revenue. The fiscal problem here is clear: unchecked infringement leads to price wars. The solution lies in aggressive, cross-border IP enforcement, a service increasingly provided by specialized IP Litigation Specialists who understand the nuances of the Unified Patent Court.

The implications of this ruling extend far beyond the specific glucose sensors at issue. The judges established three critical precedents that will dictate litigation strategy for the remainder of the decade.

• jurisdictional Waiver: By failing to contest the UPC’s jurisdiction at the first instance, Sinocare and Menarini waived their right to appeal on those grounds. This forces defendants to front-load their procedural defenses, increasing upfront legal spend.
• Extraterritorial Reach: The court ruled that manufacturing outside the UPC territory for intended sale within it constitutes infringement. This closes the “loophole” where competitors manufacture in Asia to dodge European patents, a tactic previously exploited by generic device makers.
• Burden of Proof: The appellants failed to prove that procedural errors at the local division level led to an incorrect ruling. This sets a high bar for overturning preliminary injunctions, making the initial hearing the decisive battleground.

Abbott’s legal strategy, executed by Taylor Wessing and August Debouzy, was surgical. They targeted the distribution partner, Menarini, alongside the manufacturer, Sinocare. This pincer movement ensures that even if the product is made in China, it cannot be sold in Europe. For corporate counsel, this highlights the necessity of mapping the entire supply chain before filing suit. Companies lacking internal intelligence on their competitors’ distribution networks often find themselves consulting Corporate Investigation Firms to trace the flow of goods before initiating litigation.

The financial stakes are underscored by the broader market context. Abbott’s Diabetes Care division has been a primary growth engine, with the FreeStyle Libre system driving double-digit growth in recent fiscal years. According to Abbott’s recent investor presentations, the goal is to expand the addressable market by moving into type 2 diabetes management, a sector where cost sensitivity is higher. Sinocare’s entry strategy relied on undercutting Abbott on price. With the injunction upheld, that strategy is dead in the water for the UPC region.

“The UPC is rapidly becoming the single most important venue for medtech IP. A single preliminary injunction in The Hague can effectively clear a product from 17 markets overnight. The speed of enforcement here dwarfs the legacy national court systems.”

This sentiment reflects the shifting landscape of European IP law. The speed of the UPC—moving from filing to injunction in months rather than years—aligns with the rapid innovation cycles of digital health. But, this speed creates risk for defendants. Sinocare’s argument that the patent was likely invalid was dismissed, but the battle is not over. The main infringement proceedings are pending, and the European Patent Office (EPO) has accelerated opposition proceedings. The inventive step of EP 633 will be the next flashpoint.

Investors should watch the upcoming EPO opposition hearing this summer. If the patent is revoked at the EPO, the UPC injunction could theoretically unravel, though the Court of Appeal has shown a willingness to stand by its initial assessment of validity. For now, the market signal is clear: the barrier to entry for non-incumbent CGM manufacturers in Europe has just risen significantly.

The ruling also impacts the logistics of medical device distribution. With the court asserting jurisdiction over products intended for UPC states regardless of where they are manufactured, supply chain compliance becomes a legal imperative. Distributors like Menarini can no longer claim ignorance of the IP status of the goods they move. This necessitates a tighter integration between legal compliance and logistics operations. Multinational corporations are increasingly turning to Global Logistics Partners with built-in regulatory compliance modules to ensure that no infringing goods accidentally cross borders, triggering liability.

Abbott’s victory is a testament to the value of a coordinated European patent strategy. The joint team from Taylor Wessing and August Debouzy managed to synchronize proceedings across multiple jurisdictions, a complex feat that requires deep institutional knowledge. For mid-cap medtech firms, replicating this level of defense requires capital and expertise that often exceeds internal resources. The trend is toward consolidation, where only players with robust IP portfolios and the war chests to defend them can survive the UPC gauntlet.

As we move into Q2 2026, the focus shifts to the second preliminary injunction regarding EP 471. Abbott is seeking to expand the blockade. If successful, Sinocare’s entire European expansion plan for the GlucoMen iCan system faces an indefinite suspension. For the broader market, this ruling serves as a warning: the era of easy market entry into Europe for medical devices is over. The Unified Patent Court has teeth, and it is biting.

The trajectory is set. Innovation will continue, but it will be channeled through licensed pathways or distinct, non-infringing designs. The “copy and paste” model of hardware replication is facing its most significant legal headwind in decades. For investors scanning the medtech sector, the companies with the strongest patent fortresses and the most experienced litigation partners are the ones positioned to capture the alpha in this tightening regulatory environment.